Variable | single-dose | two-dose | multiple-dose | P value | Intergroup comparison | ||
---|---|---|---|---|---|---|---|
P1 P2 P3 | |||||||
LKS scoers | |||||||
Postop. 6-week | 69.70 ± 5.96 | 70.14 ± 7.32 | 70.67 ± 6.43 | 0.907 | – | – | – |
Postop. 12-week | 70.42 ± 8.27 | 74.25 ± 10.14 | 73.67 ± 9.05 | 0.409 | – | – | – |
VAS scoers | |||||||
POD#2 | 5.13 ± 1.45 | 4.66 ± 0.97 | 4.27 ± 1.05 | 0.099 | – | – | – |
POD#4 | 4.15 ± 1.01 | 3.91 ± 0.89 | 3.74 ± 1.04 | 0.459 | – | – | – |
Postop. 6-week | 2.26 ± 0.85 | 2.23 ± 0.95 | 2.17 ± 0.77 | 0.950 | – | – | – |
Postop. 12-week | 1.73 ± 0.43 | 1.75 ± 0.50 | 1.68 ± 0.55 | 0.909 | – | – | – |
SF-12 QoL | |||||||
PCS | |||||||
Postop. 6-week | 39.17 ± 4.24 | 40.64 ± 3.76 | 43.03 ± 5.65 | 0.049 | 0.279 | 0.027 | 0.144 |
Postop.12-week | 43.09 ± 5.97 | 45.95 ± 7.12 | 49.02 ± 6.75 | 0.024 | 0.200 | 0.004 | 0.161 |
MCS | |||||||
Postop. 6-week | 51.86 ± 5.96 | 50.51 ± 7.01 | 53.63 ± 5.25 | 0.361 | – | – | – |
Postop.12-week | 56.30 ± 7.76 | 56.69 ± 6.94 | 56.77 ± 6.87 | 0.978 | – | – | – |